Not Tagged
Not Tagged
['pcsm', 'prostate', 'brca', 'biomarker']
great summary of biomarkers for benefit for parpi in prostate cancer from different trials, different settings from dr heather cheng #asco2022 #pcsm atm and cdk12 mt - seem consistently less benefit from parpi. clear that brca2 derives most benefit 
An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family